Related Experiment Videos
Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of
H F Weisman1, T Bartow, M K Leppo
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Insights
Soluble complement receptor 1 (sCR1) effectively inhibits complement pathways, reducing inflammation and tissue damage in reperfusion injury models. This suggests sCR1 is a promising therapeutic for complement-mediated diseases.
Area of Science:
- Immunology
- Cardiovascular Research
- Pharmacology
Background:
- Complement activation via classical and alternative pathways contributes to tissue injury during ischemia and reperfusion.
- The complement system, particularly C3/C5 convertases, plays a critical role in inflammatory responses and cell damage.
- Leukocyte infiltration and formation of the C5b-9 complex exacerbate injury in affected tissues.
Purpose of the Study:
- To evaluate the efficacy of soluble complement receptor 1 (sCR1) as an inhibitor of complement activation.
- To assess the impact of sCR1 on leukocyte accumulation and endothelial injury in a rat reperfusion infarct model.
- To determine the therapeutic potential of sCR1 in mitigating complement-dependent tissue damage.
Main Methods:
- Conversion of wild-type CR1 to a soluble form (sCR1).
- Administration of sCR1 in a rat model of myocardial ischemia and reperfusion.
- Measurement of complement activation markers, leukocyte infiltration, and myocardial necrosis.
Main Results:
- sCR1 potently inhibited both classical and alternative complement pathways by targeting C3/C5 convertases.
- sCR1 significantly suppressed complement activation on the endothelium and reduced leukocyte accumulation in the infarct zone.
- sCR1 inhibited the formation of the C5b-9 attack complex and significantly reduced myocardial necrosis.
Conclusions:
- sCR1 is a potent inhibitor of complement activation and effectively reduces tissue injury in a reperfusion model.
- The therapeutic effects of sCR1 are attributed to the inhibition of complement activation, reduced leukocyte infiltration, and prevention of endothelial damage.
- sCR1 represents a promising therapeutic agent for diseases involving complement-dependent tissue injury.
Abstract:
In summary, conversion of wild-type CR1 to a soluble form (sCR1) creates a potent inhibitor of complement activation by both the classical and alternative pathways by inhibiting the C3/C5 convertases. In the rat reperfusion infarct model, sCR1 significantly suppresses complement activation at the endothelial surface of capillaries and venules. This suppression of complement activation is accompanied by reduced accumulation of leukocytes within the infarct zone, perhaps because of reduction of the generation of C5a, which promotes expression of leukocyte adhesion receptors and leukocyte chemotaxis. In addition, formation of the C5b-9 attack complex, which may contribute to direct endothelial injury, was suppressed by sCR1. The inhibition of complement activation and leukocyte infiltration by sCR1 explains the observed significant reduction in myocardial necrosis after ischemia and reperfusion. These studies have identified sCR1 as a potential agent for therapeutic intervention in diseases associated with complement-dependent tissue injury.